Instituto de Ciencia y Tecnología Dr. César Milstein, CONICET, Saladillo 2468, 1440 Ciudad de Buenos Aires, Argentina.
Antiviral Res. 2011 Nov;92(2):219-27. doi: 10.1016/j.antiviral.2011.08.006. Epub 2011 Aug 26.
Effective Foot and Mouth Disease Virus (FMDV) peptide vaccines for cattle have two major constraints: resemblance of one or more of the multiple conformations of the major VP1 antigenic sites to induce neutralizing antibodies, and stimulation of T cells despite the variable bovine-MHC polymorphism. To overcome these limitations, a chimeric antigen was developed, using Vesicular Stomatitis Virus glycoprotein (VSV-G) as carrier protein of an in tandem-dimer of FMDV antigenic site A (ASA), the major epitope on the VP1 capsid protein (aa 139-149, FMDV-C3 serotype). The G-ASA construct was expressed in the Baculovirus system to produce a recombinant protein (DEL BAC) (cloned in pCDNA 3.1 plasmid) (Invitrogen Corporation, Carlsbad, CA) and was also prepared as a DNA vaccine (pC DEL). Calves vaccinated with both immunogens elicited antibodies that recognized the ASA in whole virion and were able to neutralize FMDV infectivity in vitro. After two vaccine doses, DEL BAC induced serum neutralizing titers compatible with an "expected percentage of protection" above 90%. Plasmid pC DEL stimulated FMDV specific humoral responses earlier than DEL BAC, though IgG1 to IgG2 ratios were lower than those induced by both DEL BAC and inactivated FMDV-C3 after the second dose. DEL BAC induced FMDV-specific secretion of IFN-γ in peripheral blood mononuclear cells of outbred cattle immunized with commercial FMDV vaccine, suggesting its capacity to recall anamnestic responses mediated by functional T cell epitopes. The results show that exposing FMDV-VP1 major neutralizing antigenic site in the context of N-terminal sequences of the VSV G protein can overcome the immunological limitations of FMDV-VP1 peptides as effective protein and DNA vaccines for cattle.
用于牛的有效口蹄疫病毒(FMDV)肽疫苗有两个主要限制:一种或多种主要 VP1 抗原表位的多种构象相似,以诱导中和抗体,以及刺激 T 细胞,尽管存在牛 MHC 多态性。为了克服这些限制,开发了一种嵌合抗原,使用水疱性口炎病毒糖蛋白(VSV-G)作为 FMDV 抗原表位 A(ASA)串联二聚体的载体蛋白,该抗原位于 VP1 衣壳蛋白的主要表位(aa139-149,FMDV-C3 血清型)。G-ASA 构建体在杆状病毒系统中表达,以产生重组蛋白(DEL BAC)(克隆在 pCDNA3.1 质粒中)(Invitrogen Corporation,Carlsbad,CA),并作为 DNA 疫苗(pC DEL)制备。用两种免疫原接种的小牛产生的抗体可识别整个病毒粒子中的 ASA,并能体外中和 FMDV 的感染性。接种两剂疫苗后,DEL BAC 诱导的血清中和效价与“预期保护率”超过 90%相兼容。与 DEL BAC 和第二剂后诱导的灭活 FMDV-C3 相比,质粒 pC DEL 更早地刺激了 FMDV 特异性体液反应,但 IgG1 与 IgG2 的比值低于 DEL BAC 和灭活 FMDV-C3。DEL BAC 诱导免疫了商业 FMDV 疫苗的杂交牛外周血单个核细胞中 FMDV 特异性 IFN-γ 的分泌,表明其能够召回由功能性 T 细胞表位介导的回忆反应。结果表明,在 VSV G 蛋白 N 端序列的背景下暴露 FMDV-VP1 主要中和抗原表位,可以克服 FMDV-VP1 肽作为牛有效蛋白和 DNA 疫苗的免疫限制。